8.00 Registration & Coffee

8:50 am Chair’s Opening Remarks

  • Damian Green Associate Professor - Clinical Research Division , Fred Hutchinson Cancer Research Center (FHCRC)

Analyzing the Landscape: Cell-Based vs Antibody-Based Anti-BCMA Therapies

9:00 am Autologous BCMA Cell Therapies for the Treatment of Multiple Myeloma

  • Shambavi Richard Associate Professor of Medicine (Hematology and Medical Oncology) , Mount Sinai Medical Center

9:30 am Advances in Antibody-Based Immunotherapy in Multiple Myeloma


  • Myeloma is still not curable
  • Novel immunotherapies will improve patient outcome
  • Off-the-shelf bispecific antibodies are ideally suited for wide spread clinical applications

10:00 am Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare?

  • Suzette Girgis Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies, Johnson & Johnson Services
  • Shambavi Richard Associate Professor of Medicine (Hematology and Medical Oncology) , Mount Sinai Medical Center
  • Mike Damore Director & Lead - Translational Oncology , Pfizer
  • Frank Kuhr Vice President, Medical Affairs North America, Menarini Silicon Biosystems


  • Navigating the current treatment landscape of multiple myeloma
  • Bispecifics vs ADCs: Looking at PFS data?
  • Can you compare cell-based vs antibody-based, based on combination rationale?
  • Response, Efficacy, PFS, OS?
  • Discussing BCMA’s potential and limitations; can we become curative?
  • Gathering early clinical information to form robust translational outcomes
  • Discussing the effect of extramedullary disease: should we sub-classify multiple myeloma?
  • What are the implications of BCMA loss for the different modalities?
  • Combination, anti-CD38 and line of therapy potentials and rationale for different modalities?
  • Clinical presentations discussion: extramedullary disease, neutropoenia, lymphoid issues, parkinsonian-like symptoms, prophylaxis, hypogammaglobinaemia

10.30 Speed Networking

Optimizing Preclinical Models & Translational Data: Mechanistic Understanding of Disease & Resistance

11:30 am Multiple Myeloma: A Clinical Perspective

  • Andrew Yee Clinical Director & Assistant Professor of Medicine, Center for Multiple Myeloma, Harvard Medical School

12:00 pm Leveraging the Findings From First in-Human GSI-plus-BCMA Clinical Trial to Understand Mechanisms of Resistance & Optimize Efficacy

  • Damian Green Associate Professor - Clinical Research Division , Fred Hutchinson Cancer Research Center (FHCRC)


  • Exploring why mechanisms of resistance to BCMA targeted therapies require further elucidation
  • Understanding the impact of BCMA antigen density on response, needing to be further characterized
  • Discussing why the approach to sequencing BCMA targeting agents may require careful consideration

12.30 Lunch

Optimizing Clinical Practice: Patient Selection, Biomarkers & Toxicities

1:30 pm Toxicity to CAR-T Cell Therapy; When You’ve Seen One CAR-T Cell Patient You’ve Seen One CAR-T Cell Patient

  • Philip McCarthy Director & Professor - Oncology & Internal Medicine, Transplant, Cellular Therapy Center & Medicine , Roswell Park Cancer Institute


  • Understanding the future of the various modalities, combinations and treatment regimes
  • Delving into the toxicities: neurotox, CRS and more
  • Exploring allogeneic CAR’s
  • Exposing long term toxicities

Development of Novel BCMA-Targeted Therapies & BCMA Beyond Multiple Myeloma

2:00 pm BCMA-ATAC: Updates on a Novel Mode of Action in Cancer Therapy

  • Andreas Pahl CSO & Executive Vice President , Heidelberg Pharma Research GmbH

2.30 Afternoon Refreshments & Networking

3:30 pm Allogeneic BCMA CAR-T Cell Therapy for the Treatment of Multiple Myeloma


  • Developing the first allogeneic cell therapy for R/R multiple myeloma – from
    bench to bedside
  • Enhancing potency and persistence of allogeneic BCMA CAR-T cells with TurboCARs
  • Testing the promise of TurboCAR technology in the clinic

4:00 pm Disrupting Conventional Approaches to CAR-T Cell Therapies with our Proprietary Technology Platform—FasTCAR


  • Exploring CD19/BCMA CAR-T for treating B-cell Non-Hodgkin Lymphoma and CD19 CAR-T for treating Adult Acute Lymphoblastic Leukemia
  • Latest data, potential and future direction

4:30 pm The Potential of Repurposing BCMA-Targeted Biologics for Treating Autoimmune Diseases

  • Eric Fedyk Senior Vice President of Strategy, Relay Therapeutics


  • Understanding the multitude of unmet medical needs which could be addressed with a BCMA-targeted biologic
  • Exploring how the pharmacology of antibodies can be similar in healthy volunteers, autoimmune and oncology patients
  • Learning how antibodies which are effective in treating hematopoietic malignancies have also been re-purposed for the effective treatment of autoimmune diseases

5:00 pm Chairs Closing Remarks & End of Conference Day 1